TOSYMRA (SUMATRIPTAN)
TOSYMRA (SUMATRIPTAN) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: TOSYMRA; Generic name: SUMATRIPTAN; Drug class: Serotonin-1b and Serotonin-1d Receptor Agonist [EPC].
| Brand name | TOSYMRA |
|---|---|
| Generic name | SUMATRIPTAN |
| Drug class | Serotonin-1b and Serotonin-1d Receptor Agonist [EPC] |
| Manufacturer | Upsher-Smith Laboratories, LLC |
| Used for | 1 INDICATIONS AND USAGE TOSYMRA is indicated for the acute treatment of migraine with or without aura in adults. TOSYMRA is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults ( 1 ) Limitations of Use : Use only if a clear diagnosis of migraine has been established ( 1 ) Not indicated for the preventive treatment of migraine ( 1 ) Not indicated for the treatment of cluster headache ( 1 ) Limitations of Use : Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with TOSYMRA, reconsider the diagnosis before TOSYMRA is administered to treat a |
| Dosage | 2 DOSAGE AND ADMINISTRATION The recommended dose of TOSYMRA is 10 mg given as a single spray in one nostril. The maximum cumulative dose that may be given in a 24-hour period is 30 mg, with doses of TOSYMRA separated by at least 1 hour. TOSYMRA may also be given at least 1 hour following a dose of another sumatriptan product. Single dose of 10 mg of nasal spray ( 2 ) Maximum dose in a 24-hour period: 30 mg; separate doses by at least one hour ( 2 ) |
| Active ingredient(s) | SUMATRIPTAN |
| Route | NASAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=015a5cf9-f246-48bc-b91e-cd730a53d8aa |